Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Business Developments

    OmniSonics Medical Technologies (Wilmington, Massachusetts), a developer of medical devices to treat vascular occlusive disease, last month reported the final close of its Series C round of financing, producing an aggregate total of $43 million for the round.
  • Product Pipeline

    Those who suffer from stroke and ultimately those with head trauma, brain injury or in cardiac arrest may in the not-too-distant future have another weapon in the physician arsenal to fight brain swelling, the result of disease or injury that often causes more damage than the original trauma.
  • Full March 1, 2004 Issue in PDF

  • Advances in stroke prevention, peripheral vascular therapy

    New developments in medical technology are often commercialized in the European market prior to their introduction in the U.S., due to the more rapid regulatory approval process and receptivity of physicians in Europe to new technologies, particularly in the interventional device segment.
  • St. Jude becomes third company with entry in U.S. CRT-D market

    St. Jude Medical (St. Paul, Minnesota) finally received its invitation from the FDA in late June to the cardiac resynchronization therapy defibrillator (CRT-D) party. While the late arrival joined the festivities nearly two years after competitors Guidant (Indianapolis, Indiana) and Medtronic (Minneapolis, Minnesota), it said it doesn't plan to enter the scene quietly and already has begun an aggressive rollout of the product in the U.S.
  • TandemHeart provides short-term alternative to VADs’ surgical risks

    After drug-eluting stents, the cardiovascular device that has attracted the most headlines and interest over the past two years is probably the ventricular assist device (VAD), a small pump seeing growing use for bridge to heart transplant or even as a destination application.
  • Report from Europe

    Acusphere (Watertown, Massachusetts) said last month that it has entered into a collaboration, license and supply agreement with Nycomed (Roskilde, Denmark) for the European development and marketing rights to Acuspheres lead product candidate, AI-700, an ultrasound contrast agent currently in Phase III clinical trials for assessing myocardial perfusion in the diagnosis of coronary heart disease.
  • Acquisitions

    Escalon Medical (Wayne, Pennsylvania) reported that the board of Drew Scientific Group (London) has recommended that its shareholders accept Escalons revised exchange offer.
  • Agreements

    CompuMed (Los Angeles, California), a medical informatics company serving healthcare with diagnostic software solutions, said that it has been awarded a five-year renewal of its contract to provide electrocardiogram (ECG) interpretation systems and services for the New York State Department of Correctional Services (NYDOCS). NYDOCS will purchase a minimum of 87 new CardioGram systems along with ongoing ECG remote interpretation services.
  • Do you provide good care in dental emergencies?

    While working in the ED one night, a nurse noticed a strange feeling around her left cheek.